文献速递胃肠外科围术期管理与 ERAS

减重手术中生物制剂偏见的合理性探讨

Bias against biologics in bariatric surgery: is it justified?
PubMed 文献 · Surg Endosc · 2025-08-14

本研究回顾性配对分析了2012至2024年间接受减重手术的自身免疫病患者,比较术前使用生物制剂单药治疗者与匹配对照的术后结局。结果显示,尽管生物制剂组ASA分级更高,但术后并发症、再入院及6个月体重减轻与对照组无显著差异,提示合理管理下生物制剂不增加手术风险。

要点

  • 生物制剂组ASA 3比例显著高于对照组(100% vs 60.0%,p=0.03)。
  • 术后伤口并发症、再入院、吻合口漏、VTE及死亡两组均无差异。
  • 6个月体重减轻两组相当(%EWL p=0.89;%TWL p=0.78)。

核心结论

  • 尽管生物制剂组ASA状态更高,术后并发症未增加,体重减轻与对照组相似。
  • 数据提示合理管理下,使用生物制剂的患者可从减重手术中获益且不增加风险。

研究设计与样本

  • 回顾性配对队列研究,纳入2012至2024年接受减重手术的患者。
  • 比较生物制剂单药治疗的自身免疫病患者与匹配对照。

主要发现

  • 生物制剂组ASA 3比例为100%,对照组为60.0%(p=0.03)。
  • 伤口并发症:生物制剂组6.7% vs 对照组0%(p=1.00)。
  • 再入院:生物制剂组0% vs 对照组6.7%(p=1.00)。
  • 两组均无吻合口漏、VTE或死亡。
  • 6个月体重减轻:%EWL 50.7±15.4% vs 53.4±19.8%(p=0.89);%TWL 19.7±6.1 vs 21.2±5.9(p=0.78)。

关键数值与推荐

  • 生物制剂在术前12个月内使用,术前6周停药,术后6周恢复。
  • 生物制剂组中46.7%患类风湿关节炎,66.7%使用TNF抑制剂。
  • 60%患者接受VSG手术。

临床怎么用

  • 术前合理停用和术后恢复生物制剂可能不增加减重手术风险。
  • 生物制剂使用患者仍可考虑减重手术,但需个体化管理。

局限性

  • 回顾性设计,存在选择偏倚可能。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is a known risk factor for autoimmune disorders. Chronic steroid treatment among these patients poses greater surgical risk, but biological/immunomodulating agents (BIA) have allowed for safer alternatives. The effects of BIA monotherapy on postoperative complications following metabolic/bariatric surgery (MBS) have not been studied. We aimed to evaluate the effects of preoperative BIA use on post-metabolic/bariatric surgery outcomes. METHODS: We conducted a retrospective matched-pair cohort study of patients who underwent bariatric surgery between 2012 and 2024. Patients were stratified into two groups: those with autoimmune disorders on BIA monotherapy vs matched controls. Patients were matched by age, BMI, and surgery type (Roux-en-Y gastric bypass [RYGB] vs vertical sleeve gastrectomy [VSG]). Paired T-tests were used to compare continuous variables. McNemar's test was used to compare dichotomous variables. RESULTS: Thirty patients (15 per group) were included in the study. Sixty percent of patients underwent VSG. Among biologic monotherapy patients, 46.7% had rheumatoid arthritis, and 66.7% of BIA were TNF inhibitors. BIAs were used within 12 months of surgery, stopped 6 weeks prior to surgery, and resumed 6 weeks after surgery. Although there was no difference in preoperative comorbidities, BIA group had a significantly higher ASA status (100% with ASA 3) compared to controls (60.0% with ASA 3, p = 0.03). Postoperatively, there were no differences in wound complications (6.7% BIA vs. 0% control, p = 1.00) or readmissions (0% BIA vs 6.7% control, p = 1.00). There were no anastomotic leaks, VTE, or death in either group. Six-month postoperative weight loss was equal between groups: (50.7 ± 15.4%EWL BIA vs 53.4 ± 19.8%EWL control, p = 0.89; %TWL (19.7 ± 6.1 [15.1-23.8] vs. 21.2 ± 5.9 [16.9-27.6], p = 0.78). CONCLUSION: Despite higher ASA status, patients on BIA did not have increased postoperative complications, and had similar weight loss to control patients after MBS. Our data suggests that when managed appropriately, patients on BIA have similar benefits from MBS without added risk.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Anyalebechi JC, Howard B, Lyo V, et al. Bias against biologics in bariatric surgery: is it justified? Surg Endosc. 2025. PMID: 40813910. doi:10.1007/s00464-025-12046-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。